

■ Time Table

Day 2, February 19 (Fri)

As of February 12

	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	
Track 1		SY9 8:00-9:40 Targeting the Tumor Microenvironment and Microbiome in the New Era of Cancer Immunotherapy				MeS01 12:00-12:50 Best Practice in Colorectal Cancer Drug Therapy		PS1 14:00-15:55 Presidential Session 1				ES15 17:40-18:30 Challenges for bridging the gap in the treatment of ABC: Highlights from 2020		Highlight of the Day 19:30-20:30			
Track 2		SY10 8:00-10:00 Perspectives in Translational Biomarker Research for Immune Checkpoint Inhibitors					MeS10 13:00-13:50 Oxiridine plus 5-FU/LV for 2nd line metastatic pancreatic cancer in Taiwan			MO1 15:25-16:20 Lower GI Tract (Colorectal Cancer) 1		ES16 17:40-18:30 Treatment Strategy for ALK positive Lung Cancer in 2021 - Viewpoint of Japanese and European Opinion Leaders					
Track 3		SY11 8:00-9:40 New Perspectives on the Treatment of Head and Neck Cancer				MeS02 12:00-12:50 How to manage intractable pain in advanced cancer patients				SY16 15:40-17:40 De-escalating and Escalating Treatment for Breast Cancer			ES22 18:40-19:30 Role of abiraterone in ER+/HER2 negative metastatic breast cancer		SY17 20:30-22:10 Current Status and Future Perspectives of Immunotherapy for Advanced Gastric Cancer		
Track 4		SY12 8:00-10:00 Cutting Edge AML Treatments					MeS11 13:00-13:50 Current strategy for B-Cell Lymphoma		O6 14:50-16:35 Palliative Care/Symptom Management			ES18 17:40-18:30 Gastric Cancer: Current Situation and Future Perspective			SY18 20:30-22:30 How to Support Patients with Cancer During a Disaster		
Track 5		PSY1 8:00-9:40 Precision Oncology in Solid Cancer (I)				MeS03 12:00-12:50 Chemotherapy for Esophageal Cancer-What You Need to Manage it Well				MO3 16:35-17:30 Head and Neck Cancer 1			ES23 18:40-19:30 The latest treatment strategy for GI cancers, focused on MSI-high Cancers				
Track 6		SY13 8:00-10:00 Advances in Molecular Therapeutics: Potential Targets and Novel Strategies					MeS12 13:00-13:50 Dual ID therapy, The beginning of a new chapter for the treatment of NSCLC			SY14 15:00-16:40 Immune Checkpoint Blockade for Gynecological Malignancies		ES17 17:40-18:30 Emerging Scientific Data in Biliary Tract Cancer			SY19 20:30-22:30 Management of Refractory Delirium among Patients with Advanced Cancer		
Track 7		AJS 8:00-10:00 ASCO/JSMO Joint Symposium AI Oncology: Development Status and Perspectives				MeS04 12:00-12:50 The front of molecular diagnosis in non-small cell lung cancer				JSMO Guideline Committee Program 16:30-17:50			ES24 18:40-19:30 Management of weight loss and anorexia associated with cancer therapy: the role of anamorelin		SY20 20:30-22:30 Influence of Recent Regulatory Changes on Clinical Trials		
Track 8			O1 10:00-11:45 Upper GI Tract				MeS13 13:00-13:50 The progress of Anti-PD-L1 antibody avelumab			O8 15:00-16:30 Clinical Trial Facilitation Program		ES19 17:40-18:30 Precision medicine for metastatic colorectal cancer - Key points at the moment					
Track 9						MeS05 12:00-12:50 Gastrointestinal cancers chemotherapy and management for complications (mainly disseminated intravascular coagulation)	MeS14 13:00-13:50 Drug usage considering the benefits of patients for head and neck cancer		O4 14:00-15:30 TR/Genomic Profiling/Genomic Medicine				ES25 18:40-19:30 An updated overview of antiemetic therapy for CIVN from the current guidelines				
Track 10				O2 10:15-11:45 NSCLC/Chemotherapy		MeS06 12:00-12:50 Practice Changing on Treatment for Hepatocellular Carcinoma	MeS15 13:00-13:50 Practice Changing on Treatment for Hepatocellular Carcinoma			O7 14:55-16:40 Tumor Agnostic Approach/ Genomic Profiling		ES20 17:40-18:30 Digital Technologies in Oncology			SY21 20:30-22:30 Cutting-Edge Perioperative Treatments for Pancreatic Cancer		
Track 11						MeS07 12:00-12:50 Novel treatment strategy for primary CD30 positive T cell lymphoma	MeS16 13:00-13:50 Our experience with the OncoPrime Dx Target Test multi-CDx system		O5 14:00-15:45 Hepatobiliary Cancer			MO4 16:40-17:40 NSCLC/TKI 1		ES26 18:40-19:30 More progress! Precision medicine in lung cancer: Current status and future directions			
Track 12					O3 10:15-11:45 Rare Cancer/Cancer of Unknown Primary	MeS08 12:00-12:50 What we can and should do for 1 percent of patient	MeS17 13:00-13:50 New insights into the treatment of follicular lymphoma			SY15 15:00-17:00 Multidisciplinary Role for Support of Decision Making: Practical Version		ES37 17:40-18:30 The Block of gastric Staging System (BS-S) has been developed for the prevention of chemotherapy-induced High Lactate in Breast Cancer Patients	ES27 18:40-19:30 Advances in the management of follicular lymphoma				
Track 13						MeS09 12:00-12:50 Therapeutic strategies with olaparib for metastatic breast cancer in the era of genomic medicine	MeS18 13:00-13:50 Future perspective of precision medicine			MO2 15:40-16:40 TR/Biomarker 1		ES21 17:40-18:30 Cancer Associated Thrombosis	ES28 18:40-19:30 Multidisciplinary treatment for neuroendocrine tumors - Current status and Future direction -				
Track 14			PAP 9:00-9:20 PAP 9:30-10:20 がんのゲノム医療	PAP 10:30-11:20 AYA 世代のがん			PAP 13:00-13:50 がんの相談支援と情報提供			PAP 15:00-15:50 小児がん	PAP 16:00-16:50 希少がん	PAP 17:00-17:50 高齢者のがん	PAP 18:00-18:50 がんのリハビリテーション				
Meeting 1 (Pre-registration Required)																ME01 16:40-17:40 Why is Biliary Tract Cancer Special?	
Meeting 2 (Pre-registration Required)																ME02 20:30-21:30 How can Young Oncologists Develop Their Career in Breast Oncology?	
Meeting 3 (Pre-registration Required)																ME03 21:15-22:15 State of the Art Management of Metastatic Urothelial Cancer in 2021	
Meeting 4 (Pre-registration Required)																ME04 21:15-22:15 What is the Optimal PARP Inhibitor for Ovarian Cancer Patients?	
																ME05 21:15-22:15 Treatment Options in Relapsed/Refractory MM	

**Explanatory Notes**

- SP =Special Session
- AJS =ASCO/JSMO Joint Symposium
- EJS =ESMO/JSMO Joint Symposium
- SJS =SIOG/JSMO Joint Symposium
- APJS =Asia-Pacific/JSMO Joint Symposium
- JS =Joint Symposium
- PSY =Presidential Symposium
- SY =Symposium
- ME =Meet the Experts
- MoS =Morning Seminar
- MeS =Medical Seminar
- ES =Evening Seminar
- PS =Presidential Session
- O =Oral Session
- MO =Mini-Oral Session
- PD =Poster Discussion Session
- Simultaneous Interpretation(E&J) Required
- E English Session
- Live Streaming Only
- Pre-recorded Video (streaming in the designated time only)